Form 4: Phathom Pharmaceuticals Director Heidi Fields Receives Equity Compensation Package

Phathom Pharmaceuticals, Inc. Director Heidi Fields was granted 10,500 Restricted Stock Units and 17,500 stock options as part of the company's Non-Employee Director Compensation Program.

Summary

• Heidi Fields, a Director of Phathom Pharmaceuticals, Inc. (PHAT), was granted 10,500 Restricted Stock Units (RSUs) on June 3, 2025.
• These RSUs were granted at a price of $0 and represent a contingent right to receive one share of common stock for each RSU.
• The RSUs are set to vest 100% on the first anniversary of the grant date or the next occurring annual meeting of stockholders, whichever comes first, contingent on Ms. Fields' continued service on the Board.
• Additionally, Ms. Fields was granted 17,500 stock options on June 3, 2025, with an exercise price of $4.95 per share.
• These stock options also vest and become exercisable on the first anniversary of the grant date or the next occurring annual meeting of stockholders, whichever comes first, subject to her continued service.
• Following these transactions, Heidi Fields beneficially owns 30,000 shares of common stock directly and 17,500 derivative stock options directly.
• The grants were made pursuant to the Issuer's Non-Employee Director Compensation Program.

Sentiment

Score: 6

Explanation: The document reports a routine and expected compensation event for a director, which is generally viewed as neutral to slightly positive as it aligns director interests with shareholders. There are no negative implications or unexpected outcomes reported.

Positives

• The equity grants align the interests of Director Heidi Fields with those of the shareholders, as the value of her compensation is tied to the company's stock performance.
• The compensation package is part of a standard Non-Employee Director Compensation Program, indicating a structured approach to governance and incentivization.

Future Outlook

The granted Restricted Stock Units and stock options are subject to future vesting, which will occur on the first anniversary of the grant date (June 3, 2026) or the next annual meeting of stockholders, whichever is earlier, provided the director continues her service on the Board.

Management Comments

• The Restricted Stock Units and stock options were granted pursuant to the Issuer's Non-Employee Director Compensation Program.

Industry Context

The granting of equity compensation, such as Restricted Stock Units and stock options, to non-employee directors is a common practice across various industries, particularly in the biotechnology and pharmaceutical sectors, to attract and retain qualified board members and align their interests with long-term shareholder value.

Comparison to Industry Standards

• The structure of this compensation, involving a mix of Restricted Stock Units and stock options with vesting conditions tied to continued service, is consistent with standard practices for non-employee director compensation in publicly traded companies, especially within the life sciences industry.
• While specific comparable companies or projects are not detailed in this filing, this type of equity grant is a widely accepted mechanism for incentivizing board members and is observed across a broad range of companies from small-cap biotechs to larger pharmaceutical firms.

Corporate Governance

Related Party Transactions

• The transaction involves the granting of equity compensation to Heidi Fields, a Director of Phathom Pharmaceuticals, Inc., which constitutes a related party transaction as she is an insider.

Stakeholder Impact

• Shareholders: The equity grants are designed to align the director's financial interests with those of the shareholders, potentially leading to decisions that enhance long-term shareholder value.
• Employees: No direct impact on employees is indicated by this specific filing, though director compensation practices can indirectly influence overall corporate culture and compensation philosophy.

Next Steps

• The Restricted Stock Units and stock options will vest on the first anniversary of the grant date (June 3, 2026) or the next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Phathom Pharmaceuticals, PHAT, Form 4, Director Compensation, Restricted Stock Units, Stock Options, Insider Transaction, Equity Compensation